Baremed Pllc Clinic/Center Medicare: Not Enrolled in Medicare Practice Location: 2651 Oak Lawn Dr, Northfield, MN 55057 Phone: 612-616-7731 |
Northfield Hospital & Clinics - Northfield Clinic Clinic/Center - Multi-Specialty Medicare: Medicare Enrolled Practice Location: 2000 North Ave, Northfield, MN 55057 Phone: 507-646-1494 |
Carleton College Clinic/Center - Student Health Medicare: Not Enrolled in Medicare Practice Location: 1 N College St, Northfield, MN 55057 Phone: 507-222-4080 Fax: 507-222-5038 |
Free Range Mental Health Pllc Clinic/Center Medicare: Medicare Enrolled Practice Location: 103 3rd St W, Northfield, MN 55057 Phone: 507-649-0433 |
River Valley Eye Professionals Clinic/Center Medicare: Medicare Enrolled Practice Location: 2019 Jefferson Rd, Suite A, Northfield, MN 55057 Phone: 507-645-9202 Fax: 507-645-9203 |
The Lux Medspa Clinic/Center Medicare: Not Enrolled in Medicare Practice Location: 502 Division St S, Northfield, MN 55057 Phone: 612-616-7731 |
Allina Health Northfield Clinic Clinic/Center Medicare: Medicare Enrolled Practice Location: 1400 Jefferson Rd, Northfield, MN 55057 Phone: 507-663-9000 Fax: 651-241-0775 |
News Archive
Scientists have discovered that the Lassa virus, which is endemic to West Africa, uses an unexpected two-step process to enter cells.
Rice University engineers hope to make life better for those with replacement joints by modeling how artificial hips are likely to rub them the wrong way.
We may view our memory as being essential to who we are, but new findings suggest that others consider our moral traits to be the core component of our identity. Data collected from family members of patients suffering from neurodegenerative disease showed that it was changes in moral behavior, not memory loss, that caused loved ones to say that the patient wasn't "the same person" anymore.
Palatin Technologies, Inc. today announced results for its second quarter ended December 31, 2009. Palatin reported net income of $4.5 million, or $0.04 per basic and diluted share, for the quarter ended December 31, 2009, compared to a net loss of $0.4 million, or $0.00 per basic and diluted share, for the same period in 2008. Total revenues in the quarter ended December 31, 2009 were $7.3 million, compared to $1.2 million for the same period in 2008.
EntreMed, Inc., today announced the presentation of data for its Phase 2 oncology drug candidate, ENMD-2076 an Aurora A/angiogenic kinase inhibitor. Data from the Phase 1 studies with ENMD-2076 in patients with multiple myeloma and relapsed or refractory leukemia were presented by EntreMed investigators during poster sessions at the 2010 American Society of Hematology Annual Meeting being held December 4-7 in Orlando, Florida.
› Verified 4 days ago